Inflammatory demyelinating diseases of the nervous system, such as multiple sclerosis (MS) or the Guillain-Barré syndrome (GBS), represent common neurologic disorders. The understanding of the pathogenesis implicated in these conditions is incomplete. It is commonly accepted that these diseases are immune mediated. An emerging body of evidence suggests that matrix metalloproteinases (MMPs) may be of paramount importance in mediating inflammatory demyelinating diseases of the central (CNS) and peripheral nervous system (PNS). Primarily, this evidence is based on studies in animal models, such as experimental autoimmune encephalomyelitis (EAE), an animal model for inflammatory demyelination of the CNS, and experimental autoimmune neuritis (EAN), a model for inflammatory demyelination of the PNS. We investigated the temporospatial expression pattern of various MMPs in both experimental models in an attempt to elucidate the role of these proteases in the pathogenesis of these disabling diseases.
[1]
H. Hartung,et al.
Matrix metalloproteinases MMP‐9 and MMP‐7 are expressed in experimental autoimmune neuritis and the guillain‐barré syndrome
,
1998,
Annals of neurology.
[2]
R. Hughes,et al.
Matrix metalloproteinase expression during experimental autoimmune neuritis.
,
1998,
Brain : a journal of neurology.
[3]
L. Steinman,et al.
Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases.
,
1994,
The Journal of clinical investigation.
[4]
H. Hartung,et al.
Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis.
,
1998,
Brain : a journal of neurology.